Form 4: Zevra Therapeutics Executive Sells Shares, Receives New Equity

Rahsaan Thompson, Zevra Therapeutics' Chief Legal & Compliance Secretary, reported the sale of common stock and the grant and vesting of restricted stock units and stock options.

Summary

• Rahsaan Thompson, Chief Legal & Compliance Secretary of ZEVRA THERAPEUTICS, INC., reported transactions involving company stock.
• On January 30, 2026, Thompson acquired 11,333 shares of common stock through the vesting and settlement of restricted stock units.
• Concurrently, Thompson sold 4,080 shares of common stock at a weighted average price of $8.8259 per share, with prices ranging from $8.58 to $9.04.
• Following these transactions, Thompson directly beneficially owns 49,919 shares of common stock.
• On January 29, 2026, Thompson was granted 37,500 restricted stock units (RSUs), which will vest one-third on January 29, 2027, and the remainder in equal annual installments.
• Also on January 29, 2026, Thompson received a grant of 75,000 stock options with an exercise price of $8.86, vesting in four equal annual installments starting January 29, 2027, and expiring on January 28, 2036.
• The sale transaction was executed pursuant to a Rule 10b5-1(c) plan adopted on March 27, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. While there's a sale of shares, it's offset by significant new equity grants (RSUs and options), indicating continued executive alignment and compensation.

Positives

• Grant of 37,500 Restricted Stock Units (RSUs) on January 29, 2026, aligning executive incentives with long-term company performance.
• Grant of 75,000 stock options on January 29, 2026, with an exercise price of $8.86, providing future upside potential.
• Vesting and settlement of 11,333 Restricted Stock Units on January 30, 2026, converting contingent rights into common stock.

Negatives

• Sale of 4,080 shares of common stock on January 30, 2026, at a weighted average price of $8.8259, reducing direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common for executives managing personal finances and diversifying holdings. The grants of RSUs and stock options are standard compensation practices in the biotechnology and pharmaceutical industry, aiming to align executive interests with long-term shareholder value.

Comparison to Industry Standards

• N/A. This filing details specific insider transactions and compensation, which are not directly comparable to industry-wide project results or company performance benchmarks. The compensation structure (RSUs, stock options) is standard for executive roles in publicly traded companies, including peers in the biotech sector like Biogen or Gilead Sciences, but specific transaction details are individual.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be perceived negatively, but the significant grants of new equity compensation (RSUs and stock options) demonstrate continued alignment of executive interests with long-term shareholder value.
• Employees: The equity grants reflect standard executive compensation practices, which may set a precedent or expectation for other employees with similar compensation structures.

Next Steps

• Vesting of 37,500 Restricted Stock Units: One-third on January 29, 2027, with remaining two-thirds in equal annual installments thereafter.
• Vesting of 75,000 Stock Options: Four equal annual installments beginning on January 29, 2027.
• Vesting of remaining 22,667 Restricted Stock Units (from the 01/30/2026 transaction): In equal annual installments after January 30, 2026.

Key Dates

Recommendation

The filing details routine insider transactions, including both sales under a pre-arranged plan and significant new equity grants. These actions are typical for executive compensation and personal financial management and do not indicate a fundamental shift in the company's prospects or the executive's confidence. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to warrant a change in investment thesis.

Keywords

ZEVRA THERAPEUTICS, ZVRA, Rahsaan Thompson, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Stock Options, Equity Grant, 10b5-1 Plan